The authors predicted PRKD3 (protein kinase D3) as a potential regulator of anti-HER2 breast cancer cell resistance and validated it as a promising target to increase lapatinib (60), as shown in Figure 13, and trastuzumab (mAb) efficacy through combinatorial treatment with PRKD inhibitors, which can be associated with an anti-PD-1 clinical response. This evidence concerns the gene PRKD3 and breast carcinoma.